Biomarkers of Maternal Physiological Readiness During the Preconception Transition

Abstract

The preconception period is increasingly recognized as a critical window for optimizing maternal and neonatal outcomes. Identifying robust biomarkers that reflect maternal physiological readiness for conception can inform individualized care, improve reproductive planning, and reduce the risk of adverse pregnancy events. This review synthesizes current evidence regarding established and emerging biomarkers of maternal readiness during the preconception transition, emphasizing their mechanisms, clinical applications, and implications for practice. The discussion integrates epidemiological data, pathophysiological underpinnings, risk stratification, diagnostic modalities, and evolving evidence-based strategies for optimizing preconception health.

Introduction

Preconception care has evolved from a narrow focus on fertility to an integrated approach encompassing metabolic, immunological, and psychological readiness for pregnancy. Maternal physiological preparedness not only influences the likelihood of conception but also impacts embryonic development, placental function, and long-term offspring health. Biomarkers that reflect the dynamic interplay of these factors are essential tools for clinicians to guide interventions. This review addresses the current landscape of maternal physiological biomarkers relevant to the preconception period, drawing on recent advances and clinical guidelines.

Epidemiology / Disease Burden

Globally, suboptimal preconception health is a significant contributor to adverse reproductive outcomes, including infertility, miscarriage, preterm birth, and congenital anomalies. Epidemiological studies indicate that up to 50% of pregnancies are unplanned, with many women entering gestation with undiagnosed or poorly controlled medical conditions. The burden is especially pronounced in populations with limited access to preconception care, where undetected metabolic or inflammatory disturbances are prevalent. By identifying women at risk through biomarkers, clinicians can intervene proactively, potentially reducing the burden of adverse outcomes on maternal and child health systems.

Pathophysiology

The physiological readiness of a woman to conceive is governed by several interdependent systems, including metabolic homeostasis, endocrine function, immune regulation, and micronutrient status. Disruptions in insulin sensitivity, chronic low-grade inflammation, dyslipidemia, and oxidative stress are increasingly recognized as pivotal in undermining reproductive competence. For instance, elevated C-reactive protein (CRP) levels reflect systemic inflammation and have been associated with reduced fecundity. Similarly, alterations in anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) levels provide insight into ovarian reserve and hypothalamic-pituitary-ovarian axis integrity. Vitamin D, homocysteine, and thyroid-stimulating hormone (TSH) concentrations also modulate reproductive potential by influencing folliculogenesis, implantation, and early placental development. Understanding these mechanistic pathways facilitates the identification of actionable biomarkers for preconception assessment.

Risk Factors

Several modifiable and non-modifiable risk factors influence maternal physiological readiness. Common modifiable risks include obesity, insulin resistance, sedentary lifestyle, poor dietary patterns, psychosocial stress, and tobacco or alcohol use. Non-modifiable factors such as advanced maternal age, genetic predisposition to metabolic or autoimmune disorders, and a history of reproductive complications also play a role. Risk stratification using biomarkers such as fasting insulin, HbA1c, AMH, CRP, and serum micronutrient levels enables personalized counseling and targeted interventions prior to conception.

Clinical Features

While preconception readiness is often subclinical, certain features may signal underlying physiological maladaptation. Menstrual irregularity, hirsutism, acanthosis nigricans, and unexplained infertility warrant further investigation. Subtle presentations, such as mild fatigue, unintentional weight changes, or mood fluctuations, may reflect underlying thyroid dysfunction, iron deficiency, or chronic inflammation. Thorough clinical assessment, alongside biomarker evaluation, is essential for comprehensive preconception care.

Diagnosis

Diagnosis of suboptimal maternal physiological readiness relies on a combination of history, physical examination, and laboratory assessment. Core biomarkers include metabolic indicators (fasting glucose, HbA1c, lipid profile), endocrine markers (AMH, FSH, LH, estradiol, TSH, prolactin), inflammatory indices (CRP, IL-6), and micronutrient levels (iron, ferritin, folate, vitamin D, vitamin B12). Advanced panels may incorporate oxidative stress markers (malondialdehyde, glutathione), homocysteine, and adipokines (leptin, adiponectin). The integration of biomarker profiles with clinical data enables tailored recommendations for preconception optimization.

Treatment & Management

Management strategies target modifiable risk factors identified through biomarker surveillance. Metabolic derangements are addressed with lifestyle interventions (dietary optimization, physical activity), pharmacotherapy (metformin for insulin resistance), and micronutrient supplementation (folic acid, vitamin D, iron as indicated). Endocrine imbalances may require thyroid hormone replacement or ovulation induction agents. Psychosocial support and counseling are integral to managing stress-related or behavioral contributors. Early intervention, guided by biomarker trends, enhances the efficacy of preconception care and supports optimal maternal-fetal outcomes.

Recent Advances / Emerging Therapies

Recent years have witnessed significant progress in identifying novel biomarkers and leveraging omics technologies for preconception assessment. Proteomic and metabolomic signatures offer multidimensional insights into maternal readiness, with candidates such as microRNAs, exosomal markers, and reproductive tract microbiome profiles under active investigation. Machine learning algorithms applied to biomarker panels show promise in predicting reproductive outcomes. Additionally, point-of-care biomarker testing is becoming more accessible, enabling real-time risk stratification and intervention. These advances hold potential to refine personalized preconception care pathways and improve precision health strategies.

Guideline Recommendations

Current guidelines from organizations such as the American College of Obstetricians and Gynecologists (ACOG), Royal College of Obstetricians and Gynaecologists (RCOG), and World Health Organization (WHO) emphasize the importance of preconception risk assessment and optimization. Recommendations include universal screening for anemia, thyroid disorders, diabetes, and micronutrient deficiencies, with targeted use of ovarian reserve markers and inflammatory indices in high-risk populations. Clinical guidelines advocate for early intervention based on biomarker abnormalities, emphasizing multidisciplinary collaboration and continuity of care from preconception to postpartum.

Conclusion

Biomarkers of maternal physiological readiness during the preconception transition are essential for identifying women at risk, guiding personalized interventions, and improving reproductive outcomes. Advances in biomarker discovery and integration with clinical practice are transforming preconception care from a reactive to a proactive paradigm. Continued research into novel biomarkers, combined with adherence to guideline-based management, will enable healthcare professionals to optimize maternal and neonatal health in the preconception period and beyond.